Neoadjuvant pembrolizumab regimen impresses in locally advanced urothelial cancer
June 17th 2020Neoadjuvant pembrolizumab plus chemotherapy achieved a high rate of pathologic downstaging to noninvasive disease and was associated with a high radical cystectomy rate in cisplatin-eligible patients with urothelial cancer.